A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours
Status:
Recruiting
Trial end date:
2026-02-27
Target enrollment:
Participant gender:
Summary
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470
in participants with advanced or metastatic solid tumours with MTAP deficiency. The study
consists of several study modules, evaluating the safety, tolerability, PK, pharmacodynamics,
and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer
agents.